Physician profile
Ritvij Bowry
NPI 1912131053
$11,429.77
in general payments reported to CMS, 2019-2025
10 companies · $32.89 in 2025
The $32.89 reported for 2025 was less than what a typical Neurocritical Care provider received nationally (typical 2025 total: $95.82).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,734 · 2021: $11.79 · 2022: $8,287 · 2023: $364 · 2025: $32.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $6,986.75 | 2022-2023 | Andexxa |
| Portola Pharmaceuticals, LLC | $2,716.68 | 2019 | |
| Astrazeneca Uk Limited | $1,468.06 | 2022 | |
| Imperative Care, INC | $154.44 | 2023 | Zoom Rdl Radial Access System, 103cm |
| Edwards Lifesciences Corporation | $42.04 | 2022 | |
| Becton, Dickinson and Company | $32.89 | 2025 | |
| Boston Scientific Corporation | $17.12 | 2019 | |
| Xeris Pharmaceuticals, INC. | $11.79 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritvij Bowry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.